Accumulated cardiovascular and renal outcomes trials showed that SGLT2 inhibitors reduced the risk of cardiovascular and renal events, particularly HF-related events, in various patient populations, irrespective of diabetes and other clinical status [6–8]. This evidence concerns the gene SLC5A2 and diabetes mellitus.